MDS Abstracts

Abstracts from the International Congress of Parkinson’s and Movement Disorders.

MENU 
  • Home
  • Meetings Archive
    • 2024 International Congress
    • 2023 International Congress
    • 2022 International Congress
    • MDS Virtual Congress 2021
    • MDS Virtual Congress 2020
    • 2019 International Congress
    • 2018 International Congress
    • 2017 International Congress
    • 2016 International Congress
  • Keyword Index
  • Resources
  • Advanced Search
  • MDS Virtual Congress 2021

    Primary Palliative Care for Huntington Disease

    M. Harrison, D. Morrissey, F. Daly (Charlottesville, VA, USA)

    Objective: To develop a pilot program integrating primary palliative care with interdisciplinary care for Huntington disease (HD). Goals: 1) train HD team members to facilitate…
  • MDS Virtual Congress 2021

    The effect of Tuina in Traditional Chinese Medicine in treatment of Parkinson’s disease (Non-motor symptoms): a pilot clinical study

    FY. Chung, HY. Lai, CS. Yuen, HW. Lam, KY. Lai, SM. Chan, M. Li, KK. Chua (Hong Kong, Hong Kong)

    Objective: To evaluate the efficacy and safety of Tuina treatment in treating non-motor symptoms (NMS) of Parkinson’s disease (PD) and provide preliminary data for conducting…
  • MDS Virtual Congress 2021

    Adopting a low-cost multidisciplinary telemedicine approach for falls prevention in Parkinson´s Disease.

    A. García-Bustillo, JM. Ramírez-Sanz, JL. Garrido-Labrador, A. Arnaiz-González, F. Valiñas-Sieiro, M. Allende-Río, JJ. González-Bernal, J. González-Santos, JF. Díez-Pastor, M. Jahouh, JM. Trejo-Gabriel-Galán, E. Cubo (Burgos, Spain)

    Objective: Healthcare services have been compromised during the COVID-19 pandemic, owing to limited access to multidisciplinary care. Our main aims are to describe the methods…
  • MDS Virtual Congress 2021

    Measuring progression of Parkinson’s disease cardinal signs in the Phase 2 SPARK study

    KP. Kilambi, T. Dam, J. Edgerton, T. Fox, S. Khan, J. Xiao, M. Yang, P. Bergethon (Cambridge, USA)

    Objective: To evaluate a novel quantitative measure of Parkinson’s disease (PD) severity and progression in a Phase II clinical trial. Background: Cinpanemab, a monoclonal antibody,…
  • MDS Virtual Congress 2021

    Defining LRRK2-PD subsets based on olfactory function in the PPMI

    K. Marek, A. Siderowf, C. Tanner, T. Simuni, L. Chahine, M. Brumm, C. Coffey (New Haven, USA)

    Objective: A major goal of the Parkinson Progression Marker Initiative (PPMI) is to identify clinical and biomarker defined disease subsets that may demonstrate differing disease…
  • MDS Virtual Congress 2021

    Celiac disease-related antibodies in Parkinson’s Disease patients: a case control study.

    GUL. şahbaz, BOB. Barut, SDT. Tekol (Istanbul, Turkey)

    Objective: To compare anti-transglutaminase and antigliadin antibodies between Parkinson’s disease patients and healthy controls. A detailed gastrointestinal symptom investigation was studied and compared between patient…
  • MDS Virtual Congress 2021

    Potential drug-drug interactions in hospitalized patients with Parkinson’s disease from tertiary center in Serbia

    D. Aleksic, S. Stefanovic, M. Milosavljevic, J. Milosavljevic, S. Jankovic (Kragujevac, Serbia)

    Objective: The aim of this study was to identify predictors of potential drug-drug interactions in patients suffering from Parkinson’s disease.The aim of this study was…
  • MDS Virtual Congress 2021

    VMAT2 OVEREXPRESSION REDUCES INTRACELLULAR NEUROMELANIN LEVELS AND ATTENUATES PARKINSON-LIKE PATHOLOGY IN NEUROMELANIN-PRODUCING PARKINSONIAN RATS

    J. Compte, M. González, A. Nicolau, T. Cuadros, J. Romero, A. Parent, A. Laguna, M. Vila (Barcelona, Spain)

    Objective: Because neuromelanin derives from the oxidation of free cytosolic dopamine, we hypothesized that enhancing dopamine vesicular encapsulation with vesicular monoamine transporter 2 (VMAT2) will…
  • MDS Virtual Congress 2021

    Levodopa-Carbidopa Intestinal Gel Therapy for Advanced Parkinson’s Disease: A Single Center ‘Real World’ Study of Patients with and without DBS

    P. Dole, S. Green, M. Wiggins, J. Joseph, M. Gaspari, M. Siddiqui (Winston-Salem, USA)

    Objective: To examine the efficacy and safety of LCIG in a ‘real world’ tertiary care center setting in patients with and without DBS. Background: Levodopa-Carbidopa…
  • MDS Virtual Congress 2021

    Opicapone Analysis of Health Economic Costs in Clinical Practice in Parkinson’s Disease UK Patients with Motor Fluctuations: Findings from the OPTIPARK Study

    A. Lees, H. Reichmann, D. Magalhães, J. Rocha, P. Soares-da-Silva (London, United Kingdom)

    Objective: To assess the influence of a 6-month treatment with opicapone (OPC) on the costs for the care of Parkinson’s disease (PD) patients. Background: OPC…
  • « Previous Page
  • 1
  • …
  • 80
  • 81
  • 82
  • 83
  • 84
  • …
  • 132
  • Next Page »

Most Viewed Abstracts

  • This Week
  • This Month
  • All Time
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Patients with Essential Tremor Live Longer than their Relatives
  • Life expectancy with and without Parkinson’s disease in the general population
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • What is the appropriate sleep position for Parkinson's disease patients with orthostatic hypotension in the morning?
  • An Apparent Cluster of Parkinson's Disease (PD) in a Golf Community
  • The hardest symptoms that bother patients with Parkinson's disease
  • Life expectancy with and without Parkinson’s disease in the general population
  • Effect of marijuana on Essential Tremor: A case report
  • Increased Risks of Botulinum Toxin Injection in Patients with Hypermobility Ehlers Danlos Syndrome: A Case Series
  • Covid vaccine induced parkinsonism and cognitive dysfunction
  • Estimation of the 2020 Global Population of Parkinson’s Disease (PD)
  • Patients with Essential Tremor Live Longer than their Relatives
  • Help & Support
  • About Us
  • Cookies & Privacy
  • Wiley Job Network
  • Terms & Conditions
  • Advertisers & Agents
Copyright © 2025 International Parkinson and Movement Disorder Society. All Rights Reserved.
Wiley